INFUSION PROVIDERS ALLIANCE for INFUSION PROVIDERS ALLIANCE
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELLIOTT WARREN New | — |
Health Issues HCR
Advocating for access to and reimbursement for biosimilars.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELLIOTT WARREN New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.